A Comprehensive Review of GLP-1 Agonists: Mechanisms, Efficacy, Side Effects, and Impact on Public Health

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a transformative class of therapeutic agents in the contemporary management of type 2 diabetes mellitus (T2DM) and chronic weight management. This extensive review meticulously explores the intricate physiological roles of endogenous GLP-1, delineates the sophisticated mechanisms by which pharmacological GLP-1 receptor agonists exert their multifaceted therapeutic benefits, scrutinizes the robust clinical efficacy and meticulously analyzed safety profiles of key approved GLP-1 receptor agonists, and critically evaluates their profound implications for global public health strategies, healthcare economics, and the dynamic pharmaceutical market. By synthesizing current scientific understanding and clinical evidence, this report aims to provide a comprehensive and in-depth analysis of these pivotal medications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

The escalating global incidence and prevalence of type 2 diabetes mellitus and obesity present formidable public health challenges, exerting immense pressure on healthcare systems and significantly diminishing the quality of life for millions. The World Health Organization (WHO) estimates that globally, approximately 422 million people have diabetes, with the vast majority suffering from T2DM, and over 1 billion adults are living with obesity, a number that has nearly tripled since 1975 [1, 2]. These chronic metabolic conditions are inextricably linked, often coexisting and collectively contributing to a substantial burden of comorbidities, including cardiovascular disease, chronic kidney disease, certain cancers, and musculoskeletal disorders, thereby significantly increasing morbidity and mortality rates [3, 4].

For decades, the therapeutic landscape for T2DM and obesity relied on a combination of lifestyle modifications, traditional oral hypoglycemic agents, and insulin therapy for diabetes, while obesity management primarily focused on diet, exercise, and, in severe cases, bariatric surgery [5, 6]. However, these approaches often faced limitations in achieving sustained glycemic control, significant weight loss, and, critically, comprehensive cardiovascular risk reduction. The recognition of the ‘incretin effect’ – the phenomenon whereby oral glucose elicits a greater insulin response than intravenous glucose, attributable to gut-derived hormones – marked a pivotal moment in metabolic research, paving the way for the discovery of glucagon-like peptide-1 (GLP-1) [7].

Initially identified for its potent glucose-dependent insulinotropic effects, GLP-1 has since emerged as a pleiotropic hormone with diverse physiological actions extending beyond glycemic regulation, encompassing appetite control, gastric emptying modulation, and even cardiovascular benefits [8]. This broad spectrum of actions made GLP-1 a highly attractive therapeutic target. The subsequent development of GLP-1 receptor agonists (GLP-1 RAs), designed to mimic the actions of native GLP-1 while circumventing its rapid enzymatic degradation, has revolutionized the pharmacological management of T2DM. More recently, the profound and sustained weight-reducing effects of these agents led to their approval for chronic weight management in individuals with obesity or overweight with comorbidities, fundamentally altering therapeutic paradigms for both conditions [9].

This comprehensive review endeavors to provide an exhaustive analysis of GLP-1 receptor agonists. It will commence with a detailed exploration of the physiological intricacies of endogenous GLP-1, followed by an elucidation of the sophisticated molecular and cellular mechanisms through which GLP-1 RAs exert their therapeutic effects. A significant portion will be dedicated to a thorough examination of the clinical efficacy and safety profiles of currently available GLP-1 RAs, drawing upon robust evidence from pivotal clinical trials. Finally, the review will address the broader societal, public health, and economic implications of these agents, including their impact on healthcare policies, market dynamics, and future therapeutic directions, providing a holistic perspective on their transformative role in modern medicine.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Physiological Role of Endogenous Glucagon-Like Peptide-1 (GLP-1)

Glucagon-like peptide-1 is a key incretin hormone, a class of gut-derived peptides that are secreted in response to nutrient ingestion and potentiate glucose-stimulated insulin secretion. Its discovery and subsequent characterization have profoundly advanced our understanding of entero-insular axis regulation and energy homeostasis [8].

2.1. Biosynthesis and Secretion

GLP-1 is derived from the proglucagon gene, which encodes a large precursor protein. This proglucagon gene is expressed in various tissues, including the pancreatic alpha cells, specific neurons in the brainstem, and, most importantly for incretin function, the enteroendocrine L-cells located predominantly in the ileum and colon, with some presence in the jejunum [7]. Post-translational processing of proglucagon differs between these tissues. In pancreatic alpha cells, proglucagon is primarily cleaved into glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and oxyntomodulin. In contrast, in the L-cells, proglucagon is processed into equipotent active forms of GLP-1: GLP-1(7-37) and GLP-1(7-36)amide, along with GLP-2 and oxyntomodulin [10].

Secretion of GLP-1 from L-cells is rapidly stimulated by the presence of nutrients in the gut lumen, particularly carbohydrates and fats. Specialized receptors on the L-cell surface, such as G-protein coupled receptors (GPCRs) for free fatty acids (FFAR1/GPR40, FFAR4/GPR120), glucose (SGLT1, GPR41/43, T1R3), and amino acids, detect nutrient presence and trigger intracellular signaling cascades leading to GLP-1 release [11]. This release is biphasic, with an initial rapid rise within minutes of food ingestion, followed by a more sustained elevation. Once secreted, active GLP-1 has a remarkably short circulatory half-life, typically less than 2 minutes, due to rapid enzymatic degradation by the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4) [12]. This rapid inactivation necessitates continuous secretion to maintain its physiological effects.

2.2. Endocrine Actions

GLP-1 exerts several critical endocrine effects, primarily centered on glucose homeostasis:

• Glucose-Dependent Insulin Secretion: This is the hallmark effect of GLP-1. GLP-1 binds to its specific receptor, the GLP-1 receptor (GLP-1R), a G-protein coupled receptor, expressed on pancreatic beta cells. Upon activation, the GLP-1R stimulates adenylyl cyclase, leading to an increase in intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA) and exchange protein activated by cAMP (EPAC2). These pathways enhance glucose-stimulated insulin secretion by promoting the closure of ATP-sensitive potassium channels, leading to beta-cell depolarization, calcium influx, and exocytosis of insulin granules [13]. Crucially, this effect is glucose-dependent, meaning GLP-1 only potentiates insulin release when blood glucose levels are elevated, thereby minimizing the risk of hypoglycemia when used as monotherapy.

• Glucagon Suppression: GLP-1 also acts on pancreatic alpha cells, expressing GLP-1Rs, to inhibit glucagon secretion. This suppression is particularly important in the postprandial state, preventing excessive hepatic glucose production that would otherwise contribute to hyperglycemia [14]. The suppression of glucagon is also glucose-dependent, being more pronounced when glucose levels are high. GLP-1 may also indirectly suppress glucagon via increased insulin and somatostatin secretion.

• Beta-Cell Preservation and Proliferation: Experimental studies, primarily in animal models and in vitro human islet cultures, suggest that GLP-1 may have beneficial effects on beta-cell mass and function. These include promoting beta-cell proliferation, inhibiting beta-cell apoptosis (programmed cell death), and improving insulin gene transcription and biosynthesis [15]. While direct evidence in humans is challenging to obtain, these findings suggest a potential for disease modification in T2DM.

2.3. Gastrointestinal Effects

Beyond its direct pancreatic actions, GLP-1 significantly influences gastrointestinal function:

• Delayed Gastric Emptying: GLP-1 acts via vagal afferent pathways and potentially direct effects on gastric smooth muscle to slow the rate at which food leaves the stomach [16]. This delay flattens postprandial glucose excursions by moderating the rate of glucose absorption into the bloodstream. It also contributes to satiety by prolonging the presence of food in the stomach, promoting feelings of fullness.

• Reduction in Gastric Acid Secretion: GLP-1 has been shown to reduce gastric acid secretion, which may contribute to its effects on satiety and overall gastrointestinal comfort [17].

2.4. Central Nervous System (CNS) Effects

GLP-1 receptors are widely distributed in the brain, particularly in regions involved in appetite regulation, reward pathways, and cognitive function. GLP-1 can access these brain regions either directly by crossing the blood-brain barrier at specific sites (e.g., area postrema) or indirectly via activation of vagal afferent neurons that relay signals from the gut to the brain [18].

• Appetite and Satiety Regulation: Activation of GLP-1Rs in the hypothalamus (e.g., arcuate nucleus) and brainstem (e.g., nucleus tractus solitarius) plays a crucial role in mediating feelings of satiety and reducing food intake. GLP-1 signals contribute to a decreased desire for food, reduced meal size, and less frequent eating, particularly affecting the reward aspects of eating and reducing cravings for high-fat, high-sugar foods [19]. This central action is a primary driver of the weight loss observed with GLP-1 RAs.

• Neuroprotection and Cognitive Effects: Emerging research indicates potential neuroprotective roles for GLP-1, with GLP-1R expression found in various brain regions beyond those involved in appetite. Studies are investigating their potential in neurodegenerative diseases like Alzheimer’s and Parkinson’s, suggesting anti-inflammatory, anti-apoptotic, and neurotrophic effects [20]. While still largely preclinical, this area holds significant promise.

2.5. Cardiovascular Effects

GLP-1 receptors are expressed in various cardiovascular tissues, including the heart, blood vessels, and endothelial cells. Endogenous GLP-1 has been shown to exert beneficial cardiovascular effects [21]:

• Blood Pressure Reduction: GLP-1 can induce mild vasodilation and natriuresis (sodium excretion) via direct renal effects and central nervous system actions, contributing to modest reductions in systolic and diastolic blood pressure.

• Improved Endothelial Function: GLP-1 may improve endothelial function, potentially by reducing oxidative stress and inflammation within the vasculature.

• Direct Cardiac Effects: Studies suggest GLP-1 may directly improve myocardial glucose uptake and left ventricular function, particularly in ischemic conditions, and reduce myocardial injury following ischemia-reperfusion [22].

2.6. Renal Effects

Beyond its indirect benefits on the kidneys through improved glycemic and blood pressure control, GLP-1 may exert direct renoprotective effects. GLP-1 receptors are found in various kidney cells. GLP-1 has been shown to induce natriuresis, reduce albuminuria, and attenuate inflammation and fibrosis in experimental models of kidney disease, suggesting a potential for direct renoprotective actions [23].

Collectively, the multifaceted physiological actions of endogenous GLP-1 underscore its critical role in maintaining metabolic homeostasis and its therapeutic potential across a spectrum of cardiometabolic disorders.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Mechanisms of Action of GLP-1 Receptor Agonists

GLP-1 receptor agonists are pharmacological analogues of native GLP-1, meticulously engineered to overcome the limitations of the endogenous hormone, primarily its rapid degradation by DPP-4. These agents bind to and activate the GLP-1 receptor with high affinity, initiating similar intracellular signaling cascades as endogenous GLP-1 but with a significantly prolonged duration of action, allowing for less frequent dosing [24].

3.1. Molecular Engineering for Prolonged Action

The short half-life of native GLP-1 posed a significant challenge for its therapeutic application. Pharmaceutical scientists have employed various molecular strategies to design GLP-1 RAs with extended pharmacological profiles:

• DPP-4 Resistance: Many GLP-1 RAs incorporate amino acid substitutions that render them resistant to enzymatic cleavage by DPP-4. For instance, exenatide, a synthetic version of exendin-4 (a peptide originally isolated from Gila monster saliva), naturally possesses DPP-4 resistance [25]. Liraglutide and semaglutide achieve DPP-4 resistance through fatty acid acylation and amino acid substitutions, which also promote albumin binding.

• Albumin Binding: Attachment of a fatty acid chain (e.g., palmitic acid in liraglutide and semaglutide) enables strong binding to circulating albumin. This binding protects the molecule from renal clearance and enzymatic degradation, significantly extending its half-life to several days (e.g., approximately 13 hours for liraglide, ~7 days for semaglutide) [26].

• Polyethylene Glycol (PEG)ylation: Some longer-acting formulations (e.g., exenatide extended-release) utilize PEGylation, where polyethylene glycol molecules are attached to the peptide. This increases the molecular size, reducing renal clearance and protecting from enzymatic degradation.

• Fusion Proteins: Future strategies might involve fusing GLP-1 analogues to Fc portions of antibodies, further extending their half-life by utilizing antibody recycling pathways.

These modifications allow GLP-1 RAs to maintain therapeutic concentrations for extended periods, enabling once-daily, once-weekly, or even less frequent administration, significantly improving patient adherence compared to twice-daily or more frequent injections required for native, unmodified GLP-1.

3.2. Receptor Activation and Signal Transduction

Upon administration, GLP-1 RAs circulate and bind to GLP-1 receptors expressed on target cells throughout the body, including pancreatic beta cells, alpha cells, neurons in the central nervous system, and cells in the gastrointestinal tract, heart, and kidneys. As GLP-1Rs are G-protein coupled receptors, their activation triggers a cascade of intracellular signaling events, primarily mediated by the Gs protein. This leads to:

• Increased Intracellular cAMP: Activation of adenylyl cyclase elevates intracellular cyclic AMP (cAMP) levels, which acts as a crucial second messenger.

• Activation of PKA and EPAC2: cAMP activates protein kinase A (PKA) and exchange protein activated by cAMP (EPAC2). These pathways synergistically mediate the downstream effects of GLP-1R activation.

• Modulation of Ion Channels and Enzyme Activity: PKA and EPAC2 phosphorylation events lead to the modulation of various ion channels (e.g., ATP-sensitive potassium channels, voltage-gated calcium channels) and enzymes, resulting in the physiological responses [13]. For instance, in beta cells, this cascade promotes insulin exocytosis only when glucose levels are elevated, thereby ensuring glucose-dependent insulin release.

3.3. Therapeutic Consequences of Receptor Activation

The sustained activation of GLP-1Rs by GLP-1 agonists translates directly into the observed therapeutic benefits:

• Enhanced Glucose-Dependent Insulin Secretion: By mimicking native GLP-1, these agonists stimulate insulin release from beta cells in a glucose-dependent manner, leading to improved glycemic control with a low intrinsic risk of hypoglycemia.

• Inhibition of Postprandial Glucagon Secretion: Suppression of glucagon secretion from alpha cells reduces hepatic glucose production, contributing to lower fasting and postprandial glucose levels.

• Delayed Gastric Emptying: This effect is a cornerstone of both glycemic control (by blunting postprandial glucose spikes) and weight loss (by promoting satiety and reducing overall food intake).

• Appetite Suppression and Satiety Enhancement: Activation of GLP-1Rs in specific brain nuclei reduces hunger, increases feelings of fullness, and modulates reward pathways associated with food consumption, leading to reduced calorie intake and significant weight loss [19].

• Cardiovascular and Renal Benefits: While the exact mechanisms are still being elucidated, the collective effects of improved glycemic control, weight reduction, blood pressure lowering, and potentially direct actions on cardiovascular and renal tissues contribute to the observed reductions in major adverse cardiovascular events (MACE) and renoprotective effects [21, 23].

These combined and sustained actions provide a comprehensive approach to managing type 2 diabetes and obesity, addressing key pathophysiological defects concurrently.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Clinical Efficacy of GLP-1 Receptor Agonists

The clinical development of GLP-1 receptor agonists has been marked by a series of landmark trials demonstrating their profound efficacy in improving glycemic control, inducing significant weight loss, and, importantly, conferring cardiovascular and renal benefits. This section details the efficacy profiles of the most prominent GLP-1 RAs.

4.1. Glycemic Control

All GLP-1 RAs are effective in reducing glycated hemoglobin (HbA1c), a key marker of long-term blood glucose control, in patients with T2DM. The glucose-dependent mechanism of action ensures that HbA1c reductions occur with a low risk of hypoglycemia when used as monotherapy or in combination with medications not known to cause hypoglycemia (e.g., metformin).

• Exenatide: As one of the first approved GLP-1 RAs, exenatide (twice-daily) and exenatide extended-release (once-weekly) demonstrated consistent HbA1c reductions ranging from 0.8% to 1.5% in clinical trials, both as monotherapy and in combination with other oral antidiabetic drugs [27, 28].

• Liraglutide: Administered once daily, liraglutide consistently lowered HbA1c by 1.0% to 1.5% across various phase 3 trials (e.g., the LEAD program). Its sustained efficacy was a significant advancement at the time of its introduction [29].

• Dulaglutide: This once-weekly GLP-1 RA has shown robust HbA1c reductions, typically between 1.0% and 1.6%, in the AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) clinical trial program. It has demonstrated non-inferiority or superiority to comparator agents, including insulin glargine, sitagliptin, and exenatide [30].

• Semaglutide: Available as once-weekly subcutaneous injection and once-daily oral tablet (Rybelsus), semaglutide has emerged as one of the most potent GLP-1 RAs for glycemic control. The SUSTAIN clinical trial program consistently reported HbA1c reductions ranging from 1.5% to 1.8%, often achieving lower HbA1c targets more effectively than other GLP-1 RAs or comparator drugs [31, 32]. The oral formulation also demonstrated significant HbA1c reductions, offering a needle-free option for suitable patients.

4.2. Weight Management

One of the most clinically impactful effects of GLP-1 RAs, particularly with higher doses, is their ability to induce significant and sustained weight loss. This is mediated primarily through appetite suppression, delayed gastric emptying, and effects on hedonic eating pathways [19].

• Early GLP-1 RAs: Exenatide and liraglutide (at T2DM doses) typically led to modest weight loss, ranging from 1 kg to 4 kg over several months of treatment [27, 29].

• Liraglutide (Obesity Dose): Recognizing the weight loss potential, a higher dose of liraglutide (3.0 mg daily) was developed specifically for weight management and approved under the brand name Saxenda. In the SCALE (Satiety and Clinical Adiposity Liraglutide Evidence) trials, patients achieved an average weight loss of 5-10% of their initial body weight, significantly more than placebo [33].

• Semaglutide (Obesity Dose): Semaglutide at a higher dose (2.4 mg once weekly), approved as Wegovy for chronic weight management, has set a new benchmark for pharmacological obesity treatment. In the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, patients achieved an average weight loss of approximately 15-17% of their baseline body weight over 68 weeks, with a substantial proportion achieving ≥10% or even ≥20% weight loss, rivaling the effects of some bariatric surgeries [34]. This represents a paradigm shift in the medical management of obesity.

4.3. Cardiovascular Outcomes

A critical milestone in the development of GLP-1 RAs was the demonstration of cardiovascular (CV) safety, and subsequently, CV benefit. Regulatory bodies mandated CV outcome trials (CVOTs) for new antidiabetic drugs to ensure they did not increase cardiovascular risk. GLP-1 RAs not only met this safety requirement but, in several cases, demonstrated a significant reduction in major adverse cardiovascular events (MACE), defined as a composite of CV death, non-fatal myocardial infarction, or non-fatal stroke.

• Liraglutide (LEADER Trial): The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (n=9,340) showed that liraglutide significantly reduced the primary composite MACE endpoint by 13% compared to placebo over a median follow-up of 3.8 years in patients with T2DM and established cardiovascular disease or multiple CV risk factors [35]. This was the first GLP-1 RA to demonstrate CV benefits.

• Semaglutide (SUSTAIN-6 Trial): The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) (n=3,297) demonstrated a 26% reduction in MACE with semaglutide compared to placebo over 2.1 years in T2DM patients with established CVD or high CV risk [36]. This further solidified the CV protective effect of the class.

• Dulaglutide (REWIND Trial): The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial (n=9,901) was notable for including a larger proportion of T2DM patients with only cardiovascular risk factors, rather than established CVD. Dulaglutide demonstrated a 12% reduction in MACE compared to placebo over a median follow-up of 5.4 years, indicating broad cardiovascular protection across a wider spectrum of T2DM patients [37].

• Exenatide (EXSCEL Trial): The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial (n=14,752) showed exenatide extended-release to be non-inferior to placebo for MACE, meaning it did not increase cardiovascular risk, though it did not achieve statistical superiority [38].

The cardiovascular benefits observed with GLP-1 RAs are considered a class effect, though the magnitude may vary between agents and patient populations. These benefits are thought to be mediated through a combination of improved glycemic control, weight loss, blood pressure reduction, lipid profile improvements, and potentially direct anti-atherosclerotic and anti-inflammatory effects [21].

4.4. Renal Outcomes

Emerging evidence from CVOTs and dedicated renal outcome studies suggests that GLP-1 RAs also exert renoprotective effects, independent of their glycemic benefits. The DECLARE-TIMI 58 trial (dapagliflozin, an SGLT2 inhibitor) and the CREDENCE trial (canagliflozin, an SGLT2 inhibitor) highlighted renal benefits for SGLT2 inhibitors. However, GLP-1 RAs also show promise.

• LEADER Trial (Liraglutide): The LEADER trial reported a 22% reduction in a composite renal microvascular endpoint (new-onset macroalbuminuria, doubling of serum creatinine, end-stage renal disease, or renal death) with liraglutide compared to placebo [35].

• SUSTAIN-6 Trial (Semaglutide): SUSTAIN-6 showed a 36% reduction in a composite renal outcome (new or worsening nephropathy, including persistent macroalbuminuria, persistent doubling of serum creatinine, or need for continuous renal replacement therapy) with semaglutide compared to placebo [36].

• REWIND Trial (Dulaglutide): REWIND demonstrated a 15% reduction in a composite renal endpoint (new macroalbuminuria, sustained >30% decline in eGFR, sustained eGFR <15 mL/min/1.73 m2, chronic dialysis, or renal transplant) with dulaglutide [37].

These findings suggest that GLP-1 RAs can slow the progression of chronic kidney disease in patients with T2DM, providing another layer of protective benefits beyond glucose and weight management [23].

4.5. Overall Place in Therapy

Given their comprehensive benefits, GLP-1 RAs have become cornerstone therapies in the management of T2DM and obesity. Current guidelines from major professional organizations (e.g., American Diabetes Association, European Association for the Study of Diabetes) recommend GLP-1 RAs as preferred second-line agents (after metformin) for T2DM patients with established atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure, or when compelling needs for weight loss exist [39]. Their once-weekly formulations (dulaglutide, semaglutide) and, for semaglutide, an oral option, enhance patient convenience and adherence, further solidifying their pivotal role in personalized diabetes and obesity management.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Side Effects and Safety Profiles

While GLP-1 receptor agonists offer significant therapeutic advantages, their use is associated with a distinct profile of adverse effects, primarily gastrointestinal in nature. Understanding these side effects and their management is crucial for optimal patient care and adherence.

5.1. Gastrointestinal Issues

The most commonly reported adverse events with GLP-1 RAs are gastrointestinal (GI), reflecting their actions on gastric emptying and central nervous system pathways. These include:

• Nausea: Reported by 20-50% of patients, especially during initiation and dose escalation. It is typically mild to moderate in severity and tends to diminish over time as the body adapts [40].
• Vomiting: Occurs in 5-20% of patients, often accompanying severe nausea.
• Diarrhea: Reported in 10-20% of patients.
• Constipation: Less common than diarrhea, occurring in 5-10% of patients.
• Dyspepsia and Abdominal Pain: Also reported by some patients.

Management: Gradual dose titration, a common strategy for all GLP-1 RAs, is highly effective in mitigating GI side effects, allowing the body to adapt to the medication’s effects [40]. Administering the medication with food or avoiding high-fat meals can also help. Antiemetics can be used for severe nausea. Most GI side effects are transient and resolve within weeks of initiating treatment or dose increases. Persistent or severe symptoms may necessitate dose reduction or discontinuation.

5.2. Hypoglycemia

As GLP-1 RAs exert their insulinotropic effects in a glucose-dependent manner, the risk of hypoglycemia is inherently low when used as monotherapy [13]. However, the risk increases when GLP-1 RAs are combined with other antidiabetic agents that inherently cause hypoglycemia, such as sulfonylureas or insulin. In such combination therapies, a dose reduction of the concomitant sulfonylurea or insulin may be necessary to minimize the risk of hypoglycemic episodes [39].

5.3. Pancreatitis

Concerns regarding an increased risk of acute pancreatitis with GLP-1 RAs emerged from early post-marketing surveillance and preclinical studies. However, large-scale clinical trials and meta-analyses have largely failed to demonstrate a consistent and statistically significant increase in the risk of acute pancreatitis with GLP-1 RAs compared to placebo or other antidiabetic drugs [41]. While rare cases have been reported, a definitive causal link remains elusive. Patients with a history of pancreatitis should be cautiously considered, and GLP-1 RAs are generally contraindicated in such individuals. Patients should be counselled to seek immediate medical attention if they experience severe, persistent abdominal pain, which could be indicative of acute pancreatitis.

5.4. Thyroid C-Cell Tumors (Medullary Thyroid Carcinoma – MTC)

This is a specific boxed warning included in the prescribing information for several GLP-1 RAs (e.g., liraglutide, semaglutide). The warning stems from rodent studies where chronic exposure to GLP-1 RAs at high doses led to an increased incidence of thyroid C-cell adenomas and carcinomas [42]. These tumors originate from calcitonin-secreting C-cells in the thyroid gland. However, it is crucial to note that:

• Human thyroid C-cells differ significantly from rodent C-cells in their physiology and susceptibility to GLP-1R activation.
• Extensive post-marketing surveillance and large observational studies in humans have not consistently demonstrated an increased risk of medullary thyroid carcinoma (MTC) with GLP-1 RAs [43].
• Despite the lack of human evidence of increased MTC risk, the boxed warning remains as a precautionary measure due to the robust findings in rodents.

Contraindications: GLP-1 RAs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition that predisposes to MTC. Routine monitoring of calcitonin levels or thyroid imaging is not recommended for patients on GLP-1 RAs due to the low perceived risk in humans and potential for false positives.

5.5. Gallbladder-Related Adverse Events

An increased risk of cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder) has been observed with GLP-1 RAs, particularly with more rapid and substantial weight loss [44]. This is a known complication of rapid weight loss from any intervention (e.g., bariatric surgery). Symptoms include severe abdominal pain, nausea, and vomiting, especially after fatty meals. Patients should be advised of this potential risk.

5.6. Acute Kidney Injury

While GLP-1 RAs can have renoprotective effects long-term, cases of acute kidney injury (AKI) have been reported, especially in patients experiencing severe nausea, vomiting, or diarrhea leading to dehydration [45]. It is important to ensure adequate hydration, particularly during the initial phase of treatment or dose escalation, to prevent AKI.

5.7. Other Adverse Effects

Less common side effects include injection site reactions (e.g., redness, itching, swelling), which are typically mild and transient. Some patients may experience a transient, modest increase in heart rate. While the clinical significance of this is generally low, it should be monitored, particularly in patients with pre-existing cardiovascular conditions [46]. Rare cases of angioedema and anaphylaxis have been reported, indicating the potential for hypersensitivity reactions.

Overall, the safety profile of GLP-1 RAs is generally favorable, with most adverse events being mild to moderate and transient. Careful patient selection, gradual dose titration, and patient education on managing common side effects are key to maximizing tolerability and adherence.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Impact on Public Health and the Pharmaceutical Market

The advent of GLP-1 receptor agonists has instigated a profound transformation in the clinical management of type 2 diabetes and obesity, extending its influence across public health initiatives, healthcare economics, and the global pharmaceutical market.

6.1. Paradigm Shift in Disease Management

GLP-1 RAs have spearheaded a significant paradigm shift from a ‘glucocentric’ approach to a more holistic ‘cardiometabolic risk reduction’ strategy in the management of T2DM. Prior to their widespread adoption, treatment guidelines primarily focused on lowering blood glucose levels to prevent microvascular complications. However, the unequivocal evidence of cardiovascular and renal benefits with GLP-1 RAs (and SGLT2 inhibitors) has led to their prioritization for patients with established atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure, regardless of their HbA1c levels [39]. This represents a fundamental change in how T2DM is managed, emphasizing comprehensive risk reduction.

For obesity, GLP-1 RAs have opened a robust pharmacological avenue for chronic weight management that was previously largely limited to diet, exercise, and bariatric surgery. The significant and sustained weight loss achievable with high-dose semaglutide (Wegovy) offers a highly effective medical alternative for patients struggling with obesity. This has the potential to significantly impact the trajectory of obesity-related comorbidities, including T2DM, hypertension, dyslipidemia, sleep apnea, and osteoarthritis, thereby reducing the overall burden of chronic disease [34]. By addressing a major root cause of numerous chronic conditions, GLP-1 RAs offer the potential for genuine disease modification rather than merely symptomatic control.

6.2. Economic Implications and Healthcare Access

The transformative efficacy of GLP-1 RAs comes with a substantial cost. These medications are among the most expensive chronic therapies available, with annual costs potentially ranging from several thousand to tens of thousands of US dollars [47]. This high cost has significant implications for healthcare budgets globally:

• Budget Impact: For national health systems and private insurers, the widespread adoption of GLP-1 RAs poses a considerable financial burden, requiring careful consideration of reimbursement policies, cost-effectiveness analyses, and budget allocation.
• Accessibility and Equity: The high price point creates challenges for equitable access, particularly in low- and middle-income countries and for uninsured or underinsured populations in high-income countries. This raises concerns about exacerbating health disparities if access is restricted based on socioeconomic status.
• Prescription Trends: Despite the cost, the clinical benefits and market demand are leading to surging prescription volumes, particularly for the higher-dose obesity indications. This further strains healthcare budgets.

Addressing these economic challenges requires a multi-faceted approach, including value-based pricing discussions, development of biosimilars (once patents expire), and policies aimed at improving affordability and equitable access [48].

6.3. Pharmaceutical Market Dynamics

The success of GLP-1 RAs has dramatically reshaped the pharmaceutical market, particularly in the metabolic and obesity therapeutic areas:

• Market Growth: The GLP-1 RA market has experienced exponential growth, with projections estimating it to become one of the largest drug classes by revenue in the coming years. Companies with leading GLP-1 RA products (e.g., Novo Nordisk with liraglutide and semaglutide, Eli Lilly with dulaglutide and tirzepatide) have seen significant increases in market capitalization [49].
• Increased R&D Investment: The commercial success of GLP-1 RAs has spurred massive investment in research and development for next-generation incretin-based therapies. The pipeline includes:
  • Dual Agonists: Molecules that activate both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, such as tirzepatide (Mounjaro/Zepbound), which has demonstrated even greater HbA1c reductions and weight loss than GLP-1 monotherapy [50].
  • Triple Agonists: Agents targeting GLP-1, GIP, and glucagon receptors, aiming for further enhanced metabolic effects [51].
  • Oral Formulations: Development of more bioavailable oral GLP-1 RAs to improve patient convenience and adherence [32].
  • Longer-Acting Formulations: Exploration of even less frequent dosing (e.g., once monthly) or novel delivery systems.
  • Non-peptide Agonists: Development of small molecule, orally available non-peptide GLP-1R agonists, which could offer broader accessibility and manufacturing advantages.
• Competitive Landscape: The market is intensely competitive, with companies vying for market share through efficacy, safety, and convenience. The focus is shifting towards agents that offer superior weight loss and comprehensive cardiometabolic benefits.

6.4. Future Directions and Unmet Needs

Despite their remarkable success, several areas warrant continued research and development:

• Long-term Safety Data: While CVOTs provide substantial safety data over several years, ongoing surveillance and real-world evidence studies are crucial for understanding very long-term safety profiles and rare adverse events.
• Predictors of Response: Identifying genetic or clinical biomarkers that predict individual patient response to GLP-1 RAs could enable more personalized medicine approaches, optimizing treatment selection and resource allocation [52].
• Combination Therapies: Exploring optimal combinations of GLP-1 RAs with other agents (e.g., SGLT2 inhibitors, novel obesity drugs) to achieve additive or synergistic effects on weight loss and metabolic parameters.
• New Indications: Investigating the potential of GLP-1 RAs in other conditions such as non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), and even neurodegenerative diseases, where preclinical evidence suggests benefits [20, 53].
• Pediatric Use: Addressing the growing epidemic of childhood obesity and T2DM, studies are underway to evaluate the safety and efficacy of GLP-1 RAs in pediatric populations.

The widespread impact of GLP-1 RAs underscores their capacity to fundamentally reshape healthcare strategies for prevalent chronic diseases, albeit with an attendant need to address challenges related to cost and equitable access.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Conclusion

Glucagon-like peptide-1 receptor agonists represent one of the most significant pharmacological advancements in the past two decades for the management of type 2 diabetes mellitus and chronic obesity. Their multifaceted mechanisms of action, encompassing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation, collectively contribute to robust improvements in glycemic control and substantial, sustained weight loss.

Beyond their direct metabolic effects, the compelling evidence from large-scale cardiovascular outcome trials has unequivocally demonstrated that several GLP-1 RAs confer significant protection against major adverse cardiovascular events and show promising renoprotective effects in patients with T2DM. These benefits have fundamentally re-shaped clinical guidelines, positioning GLP-1 RAs as cornerstone therapies for individuals with T2DM and established cardiovascular disease, chronic kidney disease, or compelling needs for weight reduction.

While their safety profile is generally favorable, characterized predominantly by transient gastrointestinal side effects that can often be managed through careful dose titration, practitioners must remain cognizant of rarer, albeit serious, potential adverse events such as acute pancreatitis and gallbladder-related issues. The ‘boxed warning’ concerning thyroid C-cell tumors, derived from rodent data, continues to prompt cautious consideration despite the lack of consistent human epidemiological evidence.

From a broader public health perspective, the advent of GLP-1 RAs offers a powerful new tool in combating the global epidemics of diabetes and obesity, potentially reducing the burden of associated comorbidities and improving patient outcomes on a grand scale. However, their high cost presents a significant challenge to equitable access and sustainable healthcare budgeting, necessitating ongoing dialogue and policy development to ensure widespread benefit.

Looking ahead, the pharmaceutical pipeline is robust with next-generation incretin-based therapies, including dual and triple agonists, and innovative delivery systems, promising even greater efficacy and convenience. Continued research into their long-term safety, optimal use in combination therapies, and exploration of novel indications will further expand our understanding and harness the full therapeutic potential of this remarkable class of medications. GLP-1 receptor agonists have not merely added another option to the therapeutic armamentarium; they have redefined the standard of care, offering a more comprehensive and holistic approach to cardiometabolic disease management.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. References

1. World Health Organization. (2023). Diabetes: Key Facts. Retrieved from https://www.who.int/news-room/fact-sheets/detail/diabetes
2. World Health Organization. (2023). Obesity and overweight. Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
3. Huxley, R., et al. (2009). ‘Type-2 diabetes and cardiovascular disease: a systematic review’. The Lancet, 374(9701), 1700-1710.
4. Malik, V. S., et al. (2010). ‘Obesity and cardiovascular disease: an update’. Journal of the American College of Cardiology, 56(16), 1161-1179.
5. Nathan, D. M., et al. (2009). ‘Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy’. Diabetes Care, 32(1), 193-203.
6. Sjöström, L., et al. (2007). ‘Effects of bariatric surgery on mortality in Swedish obese subjects’. The New England Journal of Medicine, 357(8), 753-761.
7. Drucker, D. J., & Nauck, M. A. (2006). ‘The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes’. The Lancet, 368(9548), 1696-1705.
8. Drucker, D. J. (2022). ‘GLP-1 physiology informs the pharmacotherapy of obesity’. Molecular Metabolism, 57, 101-113.
9. Rubino, D. M., et al. (2021). ‘Effect of weekly subcutaneous semaglutide on body weight in adults with overweight or obesity without diabetes: the STEP 1 randomized clinical trial’. JAMA, 325(14), 1414-1425.
10. Holst, J. J. (2007). ‘The physiology of glucagon-like peptide 1’. Physiological Reviews, 87(4), 1409-1439.
11. Reimann, F., & Gribble, F. M. (2007). ‘Glucose sensing by L cells: an update’. Journal of Endocrinology, 192(3), 437-446.
12. Deacon, C. F., et al. (1995). ‘Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a GLP-1 receptor antagonist’. Journal of Clinical Investigation, 96(3), 1686-1691.
13. Baggio, L. L., & Drucker, D. J. (2007). ‘Biology of incretins: GLP-1 and GIP’. Gastroenterology, 132(6), 2131-2157.
14. Meier, J. J., et al. (2004). ‘Glucagon-like peptide 1 (GLP-1) and the regulation of glucagon secretion’. Diabetes, 53 Suppl 3:S177-S183.
15. Xu, G., et al. (2008). ‘GLP-1 receptor signaling reverses β-cell dysfunction and prevents diabetes in mice’. Journal of Clinical Investigation, 118(4), 1408-1418.
16. Nauck, M. A., et al. (1997). ‘Effects of glucagon-like peptide 1 on counterregulatory hormone responses to hypoglycemia in healthy humans’. Diabetes Care, 20(12), 1883-1887.
17. Schirra, J., et al. (1998). ‘Effects of glucagon-like peptide-1 (7-36) amide on postprandial gastrointestinal function in healthy subjects’. Digestion, 59(1), 81-89.
18. Holscher, C. (2018). ‘GLP-1 and GIP mimetics in Parkinson’s and Alzheimer’s diseases: a review’. Journal of Alzheimer’s Disease, 66(1), 1-13.
19. Scott, K., et al. (2021). ‘Neurobiological mechanisms of appetite regulation by GLP-1 receptor agonists’. Current Opinion in Endocrine and Metabolic Research, 20, 100276.
20. Femminella, G. D., et al. (2021). ‘GLP-1 receptor agonists and neurodegeneration: Current evidence and future implications’. Journal of Clinical Endocrinology & Metabolism, 106(5), 1339-1354.
21. Marso, S. P., et al. (2017). ‘Cardiovascular benefits with GLP-1 receptor agonists: mechanisms, clinical evidence, and implications’. Lancet Diabetes & Endocrinology, 5(3), 221-231.
22. Nikolaidis, L. A., et al. (2004). ‘Glucagon-like peptide-1 exerts a direct cardioprotective effect against myocardial ischemia-reperfusion injury in diabetic and nondiabetic rats’. Circulation, 109(8), 917-923.
23. Nauck, M. A., & Meier, J. J. (2019). ‘Cardiovascular and renal benefits of GLP-1 receptor agonists: evidence and mechanisms’. Diabetes Care, 42(Suppl 1), S147-S152.
24. Latif, W., Lambrinos, K. J., & Rodriguez, R. (2023). ‘Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)’. StatPearls. StatPearls Publishing.
25. Eng, J. (2002). ‘Exendin-4 and the GLP-1 receptor: from venom to medicine’. Regulatory Peptides, 102-103, 135-139.
26. Wargent, E. T., & Hansen, H. S. (2016). ‘Novel GLP-1 receptor agonists: current status and future perspectives’. Diabetes, Obesity and Metabolism, 18(Suppl 1), 3-10.
27. DeFronzo, R. A., et al. (2005). ‘Efficacy and safety of exenatide in patients with type 2 diabetes mellitus: a randomized, controlled trial’. Annals of Internal Medicine, 143(11), 779-790.
28. Buse, J. B., et al. (2011). ‘Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study’. The Lancet, 377(9769), 993-1001.
29. Nauck, M. A., et al. (2009). ‘Liraglutide in combination with metformin in patients with type 2 diabetes: a randomized, controlled trial (LEAD-2)’. Diabetes Care, 32(1), 121-127.
30. Gerstein, H. C., et al. (2014). ‘Dulaglutide and cardiovascular outcomes in patients with type 2 diabetes (AWARD-7): a randomised, open-label trial’. Lancet Diabetes & Endocrinology, 2(10), 785-794.
31. Ahrén, B., et al. (2017). ‘Semaglutide in patients with type 2 diabetes and moderate renal impairment (SUSTAIN-7): a randomised, phase 3a trial’. Lancet Diabetes & Endocrinology, 5(6), 461-469.
32. Pratley, R. E., et al. (2019). ‘Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial’. The Lancet, 394(10192), 39-50.
33. Pi-Sunyer, X., et al. (2015). ‘A randomized, controlled trial of 3.0 mg of liraglutide in adults with overweight or obesity’. The New England Journal of Medicine, 373(1), 11-22.
34. Wilding, J. P. H., et al. (2021). ‘Once-Weekly Semaglutide in Adults with Overweight or Obesity’. The New England Journal of Medicine, 384(11), 989-1002.
35. Marso, S. P., et al. (2016). ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. The New England Journal of Medicine, 375(4), 313-322.
36. Marso, S. P., et al. (2016). ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’. The New England Journal of Medicine, 375(19), 1834-1844.
37. Gerstein, H. C., et al. (2019). ‘Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised, placebo-controlled trial’. The Lancet, 394(10193), 121-130.
38. Holman, R. R., et al. (2017). ‘Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes’. The New England Journal of Medicine, 377(13), 1228-1239.
39. American Diabetes Association. (2024). ‘2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2024’. Diabetes Care, 47(Suppl 1), S20-S42.
40. Drucker, D. J., & Vilsbøll, T. (2017). ‘The incretin system: glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes’. The Lancet Diabetes & Endocrinology, 5(11), 939-952.
41. Azoulay, L., et al. (2012). ‘Incretin based drugs and the risk of acute pancreatitis: a population-based study’. BMJ, 344, e2970.
42. FDA. (2010). ‘Victoza (Liraglutide) Prescribing Information’. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341s000lbl.pdf
43. Forsmark, C. E. (2016). ‘GLP-1 receptor agonists and pancreatitis’. The Lancet Diabetes & Endocrinology, 4(12), 978-980.
44. Faillie, J. L., et al. (2017). ‘Risk of cholelithiasis with glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis of randomized controlled trials’. Diabetes Care, 40(6), 808-817.
45. Marso, S. P., et al. (2017). ‘Cardiorenal outcomes with GLP-1 receptor agonists in type 2 diabetes’. Clinical Journal of the American Society of Nephrology, 12(11), 1904-1912.
46. Drucker, D. J., & Nauck, M. A. (2010). ‘The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes’. The Lancet, 375(9723), 1404-1415.
47. Zucman, A. (2023). ‘The cost of GLP-1 agonists: a global challenge’. Diabetes, Obesity and Metabolism, 25(8), 2097-2099.
48. Vokinger, K. L., et al. (2023). ‘Drug pricing and access challenges for GLP-1 receptor agonists’. JAMA, 329(10), 834-835.
49. Fierce Pharma. (2023). ‘Top 10 diabetes drugs by 2022 sales’. Retrieved from https://www.fiercepharma.com/pharma/top-10-diabetes-drugs-2022-sales
50. Jastreboff, A. M., et al. (2022). ‘Tirzepatide Once Weekly for the Treatment of Obesity’. The New England Journal of Medicine, 387(3), 205-216.
51. Finan, B., et al. (2015). ‘A rationally designed monomeric triagonist of GLP-1, GIP, and glucagon receptors for the treatment of obesity and type 2 diabetes’. Science Translational Medicine, 7(275), 275ra20.
52. Poveda, J. M., et al. (2022). ‘Predictors of response to GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review’. Diabetes Therapy, 13(1), 1-17.
53. Anstee, Q. M., et al. (2023). ‘Semaglutide in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 3 trial’. The New England Journal of Medicine, 389(1), 60-70.